/BBLG

BBLG Stock - Bone Biologics Corporation

Q: What is the analyst price target for BBLG?

Analyst price target information is not currently available for BBLG.

Q: What is BBLG's market cap?

Market capitalization information is not currently available for BBLG.

Healthcare|Medical - Devices|NASDAQ

$1.83-1.45%

$0.03 (-1.45%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BBLG

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.52

52W High$7.74

52W Low$1.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-4,219,000	$-9,428,000	$-3,665,173	$-1,103,076	$-825,014
Net Income	$-4,112,000	$-8,949,000	$-1,484,620	$-1,610,685	$-1,824,690
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-4.83	$-34.01	$-31.15	$-37.35	$-35.68

Company Overview

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Visit Website

Earnings History & Surprises

BBLG

Beat Rate

69%

Last 16 quarters

Avg Surprise

+3946.9%

EPS vs Estimate

Beats / Misses

11/5

Last 12 quarters

Latest EPS

$-0.37

Q4 2025

EPS Surprise History

Q2 24

+55.9%

$-2.47vs$-5.60

Q2 24

+82.8%

$-7.86vs$-45.59

Q3 24

+51.8%

$-4.02vs$-8.34

Q4 24

-295.0%

$-14.22vs$-3.60

Q1 25

+6.2%

$-0.61vs$-0.65

Q2 25

-300.0%

$-1.92vs$-0.48

Q3 25

-129.3%

$-1.33vs$-0.58

Q4 25

+69.9%

$-0.37vs$-1.23

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Feb 25, 2026	$-0.34	—	—	—
Q4 2025	Nov 14, 2025	$-1.23	$-0.37	+69.9%	✓ BEAT
Q3 2025	Aug 14, 2025	$-0.58	$-1.33	-129.3%	✗ MISS
Q2 2025	May 12, 2025	$-0.48	$-1.92	-300.0%	✗ MISS
Q1 2025	Mar 5, 2025	$-0.65	$-0.61	+6.2%	✓ BEAT
Q4 2024	Nov 14, 2024	$-3.60	$-14.22	-295.0%	✗ MISS
Q3 2024	Aug 9, 2024	$-8.34	$-4.02	+51.8%	✓ BEAT
Q2 2024	May 14, 2024	$-45.59	$-7.86	+82.8%	✓ BEAT
Q2 2024	Apr 4, 2024	$-5.60	$-2.47	+55.9%	✓ BEAT
Q4 2023	Nov 14, 2023	$-145.89	$-29.27	+79.9%	✓ BEAT
Q3 2023	Aug 14, 2023	$-71.99	$-81.10	-12.7%	✗ MISS
Q2 2023	May 15, 2023	$-2161.73	$-331.47	+84.7%	✓ BEAT
Q1 2023	Mar 30, 2023	$-0.22	$144.12	+65609.1%	✓ BEAT
Q4 2022	Nov 14, 2022	$-360.29	$-172.94	+52.0%	✓ BEAT
Q3 2022	Aug 11, 2022	$-172.94	$-72.06	+58.3%	✓ BEAT
Q2 2022	May 13, 2022	$-288.23	$-100.88	+65.0%	✓ BEAT
Q1 2022	Mar 15, 2022	$-0.17	$-4.13	-2327.8%	✗ MISS
Q4 2021	Nov 16, 2021	—	$-9.95	—	—
Q3 2021	Aug 16, 2021	—	$-9.62	—	—

Frequently Asked Questions about BBLG

What is BBLG's current stock price?

Bone Biologics Corporation (BBLG) is currently trading at $1.83 per share. The stock has moved -1.45% today.

What is the analyst price target for BBLG?

No analyst price targets are currently available for this stock.

What sector is Bone Biologics Corporation in?

Bone Biologics Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.

What is BBLG's market cap?

Bone Biologics Corporation has a market capitalization of $0.00 billion, making it a small-cap company.

Does BBLG pay dividends?

No, Bone Biologics Corporation does not currently pay a dividend to shareholders.